SMR peptide antagonizes mortalin promoted release of extracellular vesicles and affects mortalin protection from complement-dependent cytotoxicity in breast cancer cells and leukemia cells.

Conclusions: Mortalin promotes cell proliferation, metastasis, angiogenesis, downregulate apoptotic signaling. Thus, mortalin is a potential therapeutic target for cancer immunotherapy. The novel SMRwt peptides antagonize the functions of mortalin, blocking tumor extracellular vesicle release and extracellular vesicle-mediated release of complement. This leads to decreases in breast cancer cell metastasis and allows standard treatment of these late stage tumor cells, thus having important clinical implications for late stage breast cancer chemotherapy. These findings support further investigation into the therapeutic value of the SMR peptide in cancer metastasis. PMID: 31534628 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Related Links:

Int J Angiol DOI: 10.1055/s-0039-1697921Doxorubicin is a standard treatment option for breast cancer, lymphoma, and leukemia, but its benefits are limited by its potential for cardiotoxicity. The primary objective of this study was to compare cardiac magnetic resonance imaging (CMRI) versus echocardiography (ECHO) to detect a reduction in left ventricular ejection function, suggestive of doxorubicin cardiotoxicity. We studied eligible patients who were 18 years or older, who had breast cancer or lymphoma, and who were offered treatment with doxorubicin with curative intent dosing of 240 to 300 mg/m2 body surface are...
Source: International Journal of Angiology - Category: Cardiology Authors: Tags: Rapid Communication Source Type: research
ConclusionsThis targeted methylation assay detected cancer signal across>20 cancer types with a single, fixed, low false positive rate and highly accurate TOO localization. These data support the feasibility of a single test that can screen for multiple cancers.Clinical trial identificationNCT02889978, NCT03085888.Editorial acknowledgementSarah Prins, PhD (GRAIL, Inc.), and Megan P. Hall, PhD (GRAIL, Inc.).Legal entity responsible for the studyGRAIL, Inc.FundingGRAIL, Inc.DisclosureG.R. Oxnard: Advisory / Consultancy, Officer / Board of Directors: Inivata; Honoraria (self): Guardant Health; Honoraria (self): Sysmex; Hon...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsHM are the most frequent non BC SPM in p treated from BC; frequently they are therapy related neoplasms. Deescalating chemotherapy and radiotherapy in BC and finding genetic markers of early malignancy detection are mandatory.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
This study aimed to analyze the role of postoperative treatment for BC in the development of subsequent HM. Using the French National Health Data System, we examined the HM risks in patients diagnosed with an incident primary breast cancer between 2007 and 2015, who underwent surgery as first-line treatment for BC. Main outcomes were acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), multiple myeloma (MM), Hodgkin’s lymphoma or non-Hodgkin’s lymphoma (HL/NHL), and acute lymphoblastic leukemia or lymphocytic lymphoma (ALL/LL). Analyses were censored at HM o...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSION: Petroleum ether extract of Annona squamosa seeds showed cytotoxicity towards a panel of cancer cells meanwhile non-significant cytotoxicity towards normal cells. PMID: 31554384 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
Conclusions: The abnormal location of FLT3 caused by different glycosylation status leads to the distinguishing signaling pathways. Targeting on FLT3 glycosylation may provide a new perspective for therapeutic strategies. Abbreviations: ABCG2: ATP-binding cassette transporter breast cancer resistance protein; ATF: activating transcription factor; AML: acute myeloid leukemia; CHOP: CCAAT-enhancer-binding protein homologous protein; 2-DG: 2-deoxy-D-glucose; EFS: event free survival; EPO: erythropoietin; EPOR: erythropoietin receptor; ERS: endoplasmic reticulum stress; FLT3: FMS-like tyrosine kinase 3; GPI: glycosylphosphatid...
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
Abstract A series of cis restricted 1,2,4-triazole analogs of combretastatin A-4 (CA-4) were designed and synthesized. The antiproliferative activity of these compounds was measured on hepatocellular carcinoma HepG2, leukemia HL-60, and breast cancer MCF-7 cell lines. The obtained results showed a substantial ability of the synthesized anilides to inhibit tumor growth. On HepG2 cells, 5o and 5r showed potent IC50 values of 0.10 and 0.04 μM, respectively. While on HL-60 cells, the IC50 values were 0.004 and 0.01 μM for 5b and 5i, respectively. The inhibitory activity of tubulin polymerization was eval...
Source: European Journal of Medicinal Chemistry - Category: Chemistry Authors: Tags: Eur J Med Chem Source Type: research
Contributors : Tamara Fernandez-Calero ; Charly Jehanno ; Denis Habauzit ; Stephane Avner ; Frederic Percevault ; Noureddine Boujrad ; Pascale Le Goff ; Monica Marin ; Denis Michel ; Rapha ël Métivier ; Gilles FlouriotSeries Type : Expression profiling by arrayOrganism : Homo sapiensEstrogen receptor (ER α) is central in driving the development of hormone-dependent breast cancers. A major challenge in treating these cancers is to understand and struggle endocrine resistance. We have previously shown that the Megakaryoblastic Leukemia 1 (MKL1) protein, a master regulator of actin dynamic and cellula r moti...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Publication date: November 2019Source: Journal of Functional Foods, Volume 62Author(s): Yu-Qin Zhao, Lun Zhang, Guo-Xu Zhao, Yin Chen, Kun-Lai Sun, Bin WangAbstractDoxorubicin (DOX) is a commonly used anthracycline in treatments of leukemia, lymphoma and breast cancer in humans and has been limited by its cardiotoxicity, which is manifested congestive heart failure in the worst condition. The present study showed that the marine carotenoid of fucoxanthin could exert cardioprotective effect against the DOX-induced injury in ICR mice. And then, the protective effects and mechanisms of fucoxanthin on DOX-induced injury of neo...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
Anthracyclines have been in clinical use for decades due to their anti-neoplastic effects in many cancers including breast cancer, leukaemia, lymphoma, sarcoma, lung cancer and multiple myeloma, however the effective use of these agents is limited by the danger of cardiotoxicity [1]. Incidence of cardiotoxicity in patients treated with anthracyclines varies according to cardiotoxicity definition, but has been reported as high as 26% for heart failure and 36% for left ventricular dysfunction [2,3], with the major predicting factor being anthracycline cumulative dose.
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: Editorial Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Immunotherapy | Leukemia | Nanotechnology | Polyethylene Glycol | Study | Toxicology